Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.

Close

Make a donation

Thursday, March 18, 2021

Great news for ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation program, co-lead by Annette Hay

The Canadian Cancer Trials Group (CCTG) and Queen’s researcher Annette Hay (Medicine) and Jonathan Bramson, of McMaster University, have received CFI support of more than $5 million for their project to develop a national cellular therapy translational research platform, the first of its kind globally. ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation is a collaboration between Queen’s, McMaster University, University of Calgary, University of Ottawa, Université de Montréal, and Canadian Blood Services. CFI funds will support research activities from novel cell therapy development to point-of-care cell manufacturing and multi-centre clinical trial testing for cancer treatment. This project aims to develop cell therapies as safe and viable treatment options through identifying biological mechanisms affecting safety and designing cost-effective methods for the harvest, expansion, manipulation, purification, and delivery of the cells.

Read the following articles to know more: